Patents by Inventor David A. Bumcrot

David A. Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting expression of huntingtin gene
    Patent number: 8314075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 20, 2012
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes
    Publication number: 20120282341
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.
    Type: Application
    Filed: September 10, 2010
    Publication date: November 8, 2012
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska, Jared Gollob, Akshay Vaishnaw, Christina Gamba-Vitalo
  • Compositions and Methods for Inhibiting Expression of Eg5 Gene
    Publication number: 20120136145
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: June 21, 2011
    Publication date: May 31, 2012
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE
    Publication number: 20120095076
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 19, 2012
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Compositions and methods for inhibiting expression of the MYC gene
    Patent number: 8124752
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: February 28, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Birgit Bramlage, Pamela Tan
  • Therapeutic compositions
    Patent number: 8110674
    Abstract: Therapeutic sRNA agents and methods of making and using are enclosed.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: February 7, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, David Bumcrot
  • Compositions and methods for inhibiting expression of Huntingtin gene
    Patent number: 8080532
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: December 20, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • METHOD OF TREATING NEURODEGENERATIVE DISEASE
    Publication number: 20110092565
    Abstract: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.
    Type: Application
    Filed: March 31, 2009
    Publication date: April 21, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: David Bumcrot, Matthew J. Farrer, Demetrius M. Maraganore, Hans-Peter Vornlocher
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20110054160
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: April 6, 2010
    Publication date: March 3, 2011
    Applicant: Alnylam Pharmaceuticals
    Inventors: Muthiah Manoharan, David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
    Publication number: 20110015250
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: April 5, 2010
    Publication date: January 20, 2011
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Compositions And Methods For Inhibiting Expression Of Huntingtin Gene
    Publication number: 20100298405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 25, 2010
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
    Publication number: 20100267806
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: March 12, 2010
    Publication date: October 21, 2010
    Inventors: David Bumcrot, Akin Akinc, Dinah Wen-Yee Sah, Tatiana Novobrantseva
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20100240881
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: March 10, 2010
    Publication date: September 23, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Compositions and methods for inhibiting expression of Huntingtin gene
    Patent number: 7749978
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: July 6, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression
    Publication number: 20100168206
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: December 10, 2009
    Publication date: July 1, 2010
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Compositions and methods for inhibiting expression of Eg5 gene
    Patent number: 7718629
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: May 18, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
    Publication number: 20100087508
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: September 1, 2009
    Publication date: April 8, 2010
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska
  • Compositions and Methods for Inhibiting Expression of the MYC Gene
    Publication number: 20100016405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 21, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC
    Inventors: David Bumcrot, Birgit Bramlage, Tan Pamela
  • Method of treating neurodegenerative disease
    Patent number: 7595306
    Abstract: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: September 29, 2009
    Inventor: David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE
    Publication number: 20080221055
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: November 26, 2007
    Publication date: September 11, 2008
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot